• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Shawver Laura exercised 50,000 shares at a strike of $3.15 and sold $555,065 worth of shares (50,000 units at $11.10) (SEC Form 4)

    1/7/25 6:24:27 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRY alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Shawver Laura

    (Last) (First) (Middle)
    C/O ARS PHARMACEUTICALS, INC.
    11682 EL CAMINO REAL, SUITE 120

    (Street)
    SAN DIEGO CA 92130

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ARS Pharmaceuticals, Inc. [ SPRY ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/06/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 01/06/2025 M 50,000 A $3.15 260,346 D
    Common Stock 01/06/2025 S(1) 50,000 D $11.1013(2) 210,346 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $3.15 01/06/2025 M 50,000 (3) 05/01/2032 Common Stock 50,000 $0 9,064 D
    Explanation of Responses:
    1. The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
    2. The weighted average sale price for the transaction reported was $11.1013 and the range of prices were between $11.00 and $11.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
    3. Immediately exercisable.
    /s/ Kathleen Scott, Attorney-in-Fact 01/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SPRY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPRY

    DatePrice TargetRatingAnalyst
    3/7/2025$30.00Sector Outperform
    Scotiabank
    2/10/2025$40.00Outperform
    Oppenheimer
    8/20/2024Overweight
    Cantor Fitzgerald
    8/13/2024$18.00 → $22.00Outperform → Strong Buy
    Raymond James
    8/12/2024$19.00 → $20.00Outperform
    Leerink Partners
    7/25/2024$18.00Outperform
    Raymond James
    3/5/2024$6.00 → $18.00Market Perform → Outperform
    Leerink Partners
    2/20/2024Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $SPRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc.

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      6/17/24 8:47:57 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc.

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      6/11/24 7:18:55 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc. (Amendment)

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      3/29/24 4:14:13 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on ARS Pharmaceuticals with a new price target

      Scotiabank initiated coverage of ARS Pharmaceuticals with a rating of Sector Outperform and set a new price target of $30.00

      3/7/25 8:14:43 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on ARS Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $40.00

      2/10/25 8:23:51 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on ARS Pharmaceuticals

      Cantor Fitzgerald initiated coverage of ARS Pharmaceuticals with a rating of Overweight

      8/20/24 8:45:44 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Scott Kathleen D. exercised 50,000 shares at a strike of $1.50 and sold $705,165 worth of shares (50,000 units at $14.10) (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      5/22/25 5:00:06 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Saunders Brent L sold $1,710,024 worth of shares (120,000 units at $14.25) and exercised 120,000 shares at a strike of $1.01 (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      5/22/25 5:00:11 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Fitzpatrick Alexander A exercised 100,000 shares at a strike of $5.58 and sold $1,451,513 worth of shares (102,969 units at $14.10), decreasing direct ownership by 3% to 89,613 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      5/22/25 5:00:13 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    SEC Filings

    See more
    • SEC Form 144 filed by ARS Pharmaceuticals Inc.

      144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      5/20/25 4:50:59 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by ARS Pharmaceuticals Inc.

      144 - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      5/20/25 4:48:09 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ARS Pharmaceuticals Inc.

      10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      5/14/25 7:03:05 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    Leadership Updates

    Live Leadership Updates

    See more
    • ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

      Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured

      12/19/24 5:25:09 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

      SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in presentations at the William Blair 45th Annual Growth Stock Conference and 2025 Jefferies Global Healthcare Conference in June. Details outlined below. William Blair 45th Annual Growth Stock ConferencePresentation: Tuesday, June 3, 2025Time: 11:20 a.m. CTLocation: ChicagoA live webcast of the presentati

      5/27/25 8:00:44 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

      $7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering

      5/14/25 7:00:00 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

      The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as little as $25 (if eligible) in preparation for summer travel and back-to-school SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced neffy® (epinephrine nasal spray) 1 mg is now available to patients and caregivers by prescription across the U.S. In March 2025, the U.S. Food and Drug

      5/7/25 8:00:00 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    Financials

    Live finance-specific insights

    See more
    • ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

      $7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering

      5/14/25 7:00:00 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

      SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website. A repla

      5/5/25 8:00:00 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), expanding the reach of neffy to approximately 2 million younger, school-aged children at risk of a severe allergic reaction $314.0 million in cash, cash equivalents, and short-term investments at year-end 2024, supporting an increased investment in commercialization in 2025 while maintaining an operating runway of at least three years Company to host conference call today, March 20, 2025 at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March

      3/20/25 7:00:00 AM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ra Capital Management, L.P. bought $13,289,410 worth of shares (1,401,299 units at $9.48) (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      3/27/24 7:37:52 PM ET
      $SPRY
      Biotechnology: Pharmaceutical Preparations
      Health Care